ATE162799T1 - Peptide mit thiolgeschütztem cystein zur verwendung in immuntests - Google Patents

Peptide mit thiolgeschütztem cystein zur verwendung in immuntests

Info

Publication number
ATE162799T1
ATE162799T1 AT90911054T AT90911054T ATE162799T1 AT E162799 T1 ATE162799 T1 AT E162799T1 AT 90911054 T AT90911054 T AT 90911054T AT 90911054 T AT90911054 T AT 90911054T AT E162799 T1 ATE162799 T1 AT E162799T1
Authority
AT
Austria
Prior art keywords
peptides
immune tests
thiol protected
htlv
hiv
Prior art date
Application number
AT90911054T
Other languages
English (en)
Inventor
James Blake
Carol-Ann Cole
Patrick Coleman
Nobuo Monji
John P Montana
Original Assignee
Genetic Systems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genetic Systems Corp filed Critical Genetic Systems Corp
Application granted granted Critical
Publication of ATE162799T1 publication Critical patent/ATE162799T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
    • C07K17/02—Peptides being immobilised on, or in, an organic carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT90911054T 1989-06-02 1990-06-04 Peptide mit thiolgeschütztem cystein zur verwendung in immuntests ATE162799T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36051389A 1989-06-02 1989-06-02

Publications (1)

Publication Number Publication Date
ATE162799T1 true ATE162799T1 (de) 1998-02-15

Family

ID=23418295

Family Applications (1)

Application Number Title Priority Date Filing Date
AT90911054T ATE162799T1 (de) 1989-06-02 1990-06-04 Peptide mit thiolgeschütztem cystein zur verwendung in immuntests

Country Status (12)

Country Link
EP (1) EP0474789B1 (de)
JP (1) JP3404035B2 (de)
KR (1) KR960013600B1 (de)
AT (1) ATE162799T1 (de)
AU (1) AU652919B2 (de)
CA (1) CA2056381C (de)
DE (1) DE69032009T2 (de)
DK (1) DK0474789T3 (de)
ES (1) ES2113860T3 (de)
FI (1) FI102834B1 (de)
NO (1) NO304151B1 (de)
WO (1) WO1990015071A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6008044A (en) * 1989-08-24 1999-12-28 Bioclonetics Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1) and detection of antibodies against epitope (GCSGKLIC)
US5459060A (en) * 1989-08-24 1995-10-17 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (gp41) of human immunodeficiency virus-1 (HIV-1)
US6083504A (en) * 1989-08-24 2000-07-04 Bioclonetics Incorporated Human monoclonal antibodies directed against the transmembrane glycoprotein (GP41) of human immunodeficiency virus-1 (HIV-1)
ATE164853T1 (de) * 1990-01-16 1998-04-15 Orgenics Ltd Peptide, von virus-hiv-hüllen-glycoproteinen abstammend, deren verwendung zum nachweis einer infektion dieser viren und für die impfung gegen aids
BR0015170A (pt) * 1999-10-27 2002-06-25 Innogenetics Nv Proteìnas de hcv com oxirredução reversìvel e conformação similar à nativa
JP5182069B2 (ja) * 2008-12-24 2013-04-10 Jnc株式会社 チオール基を有する刺激応答性磁性微粒子及びその利用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111924A (en) * 1976-01-05 1978-09-05 Takeda Chemical Industries, Ltd. Method for removal of thiol-protecting groups
FR2525592B1 (de) * 1982-04-26 1984-09-14 Pasteur Institut
US4689398A (en) * 1984-06-20 1987-08-25 Ortho Diagnostic Systems Inc. HTLV test using synthetic peptides
ATE98376T1 (de) * 1986-03-24 1993-12-15 Ortho Pharma Corp Synthetische htlv-iii-peptid-zusammensetzungen und ihre verwendung.
EP0247557B1 (de) * 1986-05-27 1994-04-20 F. Hoffmann-La Roche Ag HTLV-III(LAV)Decke-Peptide
GB8828097D0 (en) * 1988-12-01 1989-01-05 Wellcome Found Peptides

Also Published As

Publication number Publication date
DE69032009D1 (de) 1998-03-05
JPH04505623A (ja) 1992-10-01
FI102834B (fi) 1999-02-26
AU6053290A (en) 1991-01-07
KR920701236A (ko) 1992-08-11
FI915649A0 (fi) 1991-11-29
DK0474789T3 (da) 1998-09-28
EP0474789B1 (de) 1998-01-28
NO304151B1 (no) 1998-11-02
WO1990015071A1 (en) 1990-12-13
DE69032009T2 (de) 1998-07-23
NO914725L (no) 1992-01-29
EP0474789A1 (de) 1992-03-18
ES2113860T3 (es) 1998-05-16
FI102834B1 (fi) 1999-02-26
KR960013600B1 (ko) 1996-10-09
CA2056381C (en) 2000-08-22
AU652919B2 (en) 1994-09-15
JP3404035B2 (ja) 2003-05-06
NO914725D0 (no) 1991-11-29
EP0474789A4 (en) 1992-06-03
CA2056381A1 (en) 1990-12-03

Similar Documents

Publication Publication Date Title
PT90574A (pt) Processo de preparacao de polipeptidos e de determinacao da presenca de anticorpos de proteina latente anti-virus do papiloma
BR9106220A (pt) Antigenos sinteticos para a deterccao de anticorpos para o virus da hepatite c.
ATE109795T1 (de) Htlv-iii umhüllende peptiden.
SE8704185L (sv) Nya peptider, artificiella antigener och immunoanalystestsatser
DE69129803D1 (de) Wasserlösliche peptidanaloguen mit bindungstellen
NO891711L (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
ES550943A0 (es) Un procedimiento para preparar una proteina de fusion derivada de la secuencia de aminoacidos de la preprorrelaxina humana.
DK614987D0 (da) Syntetiske htlv-iii peptider, praeparater og anvendelser deraf
DK110190A (da) Alveolaere surfaktantproteiner
DE69032009D1 (de) Peptide mit thiolgeschütztem cystein zur verwendung in immuntests
ATE128716T1 (de) Hiv-peptide und methoden für den nachweis von hiv.
AU608413B2 (en) Mouse monoclonal antibody (5-21-3) to human immunodeficiency virus gp41 protein
ATE116660T1 (de) Künstliche peptid-zusammensetzungen mit immunoreaktiven antikörpern von htlv-1.
ES2085329T3 (es) Agente anticanceroso proteico.
ATE109158T1 (de) Rubella-e1 und c peptide.
DE69017352D1 (de) An HIV relatierte Peptide.
ATE112290T1 (de) Peptiden von retinblastoma gen produkten und antikoerper dagegen.
FI102614B1 (fi) Immunogeenisten aineiden hyvin säilyneiden aminohapposekvenssien vasta-aineita, menetelmä näiden vasta-aineiden valmistamiseksi ja niiden käyttö immuunimäärityksissä
Blake et al. Cysteine thiol-protected peptides for use in immunoassays
ES2129358A1 (es) Procedimiento de deteccion en una sola prueba de anticuerpos anti-virus de la hepatitis c, de la inmunodeficiencia humano y antigeno de superficie del virus de la hepatitis b".

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time